MorphoSys(MOR) - 2023 Q4 - Annual Report

Annual Report 2023 Our Clinical Pipeline | Clinical Programs Developed | | --- | | by Partners (Selection) | | | Most advanced development stage | | --- | --- | | Program | launchel | | Indication | | | Pelabresib | | | MANIFEST-2 / Myelofibrosis | | | MANIFEST / Myelofibrosis/essential thrombocythemia | | | Tulmimetostat | | | Advanced solid tumors/ | | | hematologic malignancies | | Non-Financial Re https://reports.n Most advanced Key Figures (IFRS) In February 2024, Incyte obtained exclusive rights world ...